ImmunityBio (IBRX) Equity Average (2015 - 2026)
ImmunityBio (IBRX) reported Equity Average of -$684.8 million for Q1 2026, down 26.98% year-over-year from -$937.8 million in Q1 2025, and down 33.77% quarter-over-quarter from -$511.9 million in Q4 2025.
ImmunityBio (IBRX) Equity Average (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 12 years of Equity Average data on file, last reported at -$684.8 million in Q1 2026.
- Equity Average for Q1 2026 came in at -$684.8 million, down 26.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$684.8 million (down 26.98% YoY), and the FY2025 annual result was -$494.3 million, up 7.96% from the prior year.
- Equity Average declined to -$684.8 million in Q1 2026 per IBRX's latest filing, from -$511.9 million in the prior quarter.
- Over five years, Equity Average peaked at -$290.7 million in Q1 2022 and troughed at -$720.8 million in Q3 2024.
- A 5-year average of -$539.6 million and a median of -$539.3 million in 2025 frame the typical range for Equity Average.
- The sharpest annual moves came in 2022 and 2025: Equity Average tumbled 144.18% in 2022, then advanced 24.16% in 2025.
- A 5-year view of Equity Average shows it stood at -$439.5 million in 2022, then decreased by 13.39% to -$498.3 million in 2023, then slipped by 23.65% to -$616.1 million in 2024, then climbed by 16.91% to -$511.9 million in 2025, then sank by 33.77% to -$684.8 million in 2026.
- Business Quant data shows IBRX's Equity Average at -$684.8 million in Q1 2026, -$511.9 million in Q4 2025, and -$546.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -684.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -684.80 Mn |
| Dec 31, 2025 | -511.94 Mn |
| Sep 30, 2025 | -546.61 Mn |
| Jun 30, 2025 | -580.15 Mn |
| Mar 31, 2025 | -539.31 Mn |
| Dec 31, 2024 | -616.15 Mn |
| Sep 30, 2024 | -720.77 Mn |
| Jun 30, 2024 | -694.18 Mn |
| Mar 31, 2024 | -638.46 Mn |
| Dec 31, 2023 | -498.29 Mn |
| Sep 30, 2023 | -527.91 Mn |
| Jun 30, 2023 | -588.45 Mn |
| Mar 31, 2023 | -490.77 Mn |
| Dec 31, 2022 | -439.45 Mn |
| Sep 30, 2022 | -425.53 Mn |
| Jun 30, 2022 | -379.77 Mn |
| Mar 31, 2022 | -290.73 Mn |
| Dec 31, 2021 | -216.93 Mn |
| Sep 30, 2021 | -174.26 Mn |
| Jun 30, 2021 | -171.96 Mn |